Recently, I made the case that the market’s sell-off of Ellie Mae (NYSE: ELLI) was overdone. Concerns about rising interest rates and slower mortgage activity were detracting from the long-term competitive advantages the company was successfully building. I even made a case that now could be a good opportunity for patient investors to initiate or add to a position.